Table 2.
Crude outcomes of patients in the different treatment arms. Data are number (proportion) of patients with known exposure to the variable except where specified
| No treatment (n = 344) | Tocilizumab (n = 88) | p valuea | Corticosteroids, intermediate–high dose (n = 117) | p valueb | Corticosteroids, pulse dose (n = 78) | p valuec | Combination (n = 151) | p valued | |
|---|---|---|---|---|---|---|---|---|---|
| Primary outcomee | 69/344 (20.1) | 10/88 (11.4) | 0.05 | 27/117 (23.1) | 0.57 | 12/78 (15.4) | 0.28 | 40/151 (26.5) | 0.13 |
| Median follow-up without the endpoint, days (IQR) | 20 (13–21) | 21 (16–21) | 0.01 | 21 (16–21) | 0.56 | 21 (12.21) | 0.55 | 20 (11–21) | 0.87 |
| Scale at day 21 | n = 344 | n = 88 | — | n = 117 | — | n = 78 | — | n = 151 | — |
| 1 | 253 (73.5) | 70 (79.5) | 80 (68.4) | 55 (70.5) | 100 (66.2) | ||||
| 2 | 10 (2.9) | 2 (2.3) | 4 (3.4) | 2 (2.6) | 8 (5.3) | ||||
| 3 | 16 (4.7) | 8 (9.1) | 8 (6.8) | 8 (10.3) | 14 (9.3) | ||||
| 4 | 4 (1.2) | 0 | 0 | 1 (1.3) | 1 (0.7) | ||||
| 5 | 19 (5.5) | 6 (6.8) | 2 (1.7) | 4 (5.1) | 9 (6.0) | ||||
| 6 | 1 (0.3) | 0 | 1 (0.9) | 0 | 19 (6.0) | ||||
| 7 (death) | 41 (11.9) | 2 (2.3) | 0.004 | 22 (18.8) | 0.08 | 8 (10.3) | 0.84 | 19 (12.6) | 0.88 |
| Scale ≤3 | 279 (81.1) | 80 (90.9) | 0.02 | 92 (78.6) | 0.56 | 65 (83.3) | 0.64 | 122 (80.8) | 0.93 |
| Digestive tract bleeding | 2/341 (0.6) | 1/88 (1.1) | 0.49 | 1/115 (1.4) | 1.0 | 1/74 (1.4) | 0.44 | 3/150 (2.0) | 0.16 |
| Secondary bacterial infection | 36/339 (10.3) | 11/88 (12.5) | 0.57 | 10/115 (8.7) | 0.72 | 8/75 (10.7) | 1.0 | 18/150 (12.0) | 0.64 |
IQR, interquartile range.
a
For tocilizumab versus no treatment.
b
For corticosteroids, intermediate-high dose versus no treatment.
c
For corticosteroids, pulse dose versus no treatment.
d
For combination versus no treatment.
e
P values obtained by univariate Cox regression except for combination therapy, for which logistic-regression was used.